News Hub | News Direct

Applied UV (NASDAQ: AUVI) Effectively Doubles Its Size Via Two Mergers, Positions Itself For Potentially Significant Future Revenue Growth

Applied UV, Inc.

Since 2019, Applied UV (NASDAQ: AUVI) has been on a mission to eradicate pathogens via its portfolio of disinfection technologies. Blending air purification machines with industry-first drain and sink sterilization, Applied UV’s product portfolio is an eclectic mix of award-winning pathogen killers. Its Sterilumen Airocide ® devices were designed for use by NASA and won the Edison Awards for Excellence in new product and service development in 2014. Its two other product lines, Scientific Air and Lumicide are used in a number of hospitals across the U.S. In 2019, the importance of sterilization technology took an unprecedented leap as the COVID-19 pandemic shocked the globe. Applied UV had a direct role to play in the fight against this pandemic, issuing its products for sale to areas with high human congestion and vulnerability like hospitals. The pandemic only strengthened Applied UV on its mission to create healthier and safer spaces for people to live, work and play. Their primary mode of doing so is through the development and acquisition of high-quality, infection-prevention technology in the healthcare, hospitality and commercial markets. On Dec. 19, Applied UV announced two mergers with Puro Lighting LLC and LED Supply Co. that effectively “doubled the size of the company,” reportedly positioning it for “significant future revenue growth.” Applied UV Merges With Puro Lighting LLC And LED Supply Co. Applied UV’s two “mergees” offer unique benefits to the company. Puro Lighing LLC, for example, has a host of ultra-violet (UV) light disinfection devices that are applicable to indoor spaces like hospitals, schools, universities, medical and manufacturing facilities, transportation, office buildings and much more. The company’s portfolio may have an edge over competitors, as UV technology is far less invasive than its chemical counterparts. Additionally, Puro has an existing relationship with Acuity Brands Inc. (NYSE: AYI), a lighting and building management firm, to which Applied UV now has access. LED Supply Co, on the other hand, is a major distributor and manufacturer of state-of-the-art LED fixtures and is one of the fastest-growing companies according to Forbes. Since its inception, LED Supply Co. has completed over 2,500 LED lighting and controls projects throughout North America. According to Applied UV, the strategic mergers of privately-held Puro Lighting LLC and LED Supply Co. will allow the company to expand into international vertical markets and improve its distribution throughout North America. The mergers, alongside the 2021 acquisitions of Airocide®, KES Science & Technology, and Scientific Air Management, create one of the broadest portfolios of patented disinfection technologies on the market today, capable of treating everything from schools and hospitals to agricultural products like cannabis. In broader terms, the current mergers allow Applied UV to tap into PURO’s capable sales team, target new markets, more easily serve commercial facilities and leverage PURO’s technology to bring it to a broader range of customers. “With an estimated additional $18 million in revenue for the 12 months ending September 30, 2022, the PURO and LED Supply mergers effectively double the size of our company,” said Max Munn, Applied UV Founder and President. “We anticipate that the combined company is likely to generate approximately $45-50 million of revenues in FY 2023, with a strong balance sheet to support the revenue growth. Further, we anticipate significant cost savings through synergies that will reduce our overhead expenses and therefore improve our margins.” Applied UV entered into definitive agreements effective December 19, 2022, to merge with both PURO Lighting and LED Supply with a transaction value of approximately $20 million. The approximate $20 million deal in consideration for this transaction is a combination of cash and restricted common and preferred shares. The restricted common and preferred shares have a $2 value, significantly above current market prices. Click here for more on Applied UV. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/

December 28, 2022 08:00 AM Eastern Standard Time

News Release

8 Best Custom Writing Services Available Online Today

Genuine Papers

How do you make the best of your time in school? How do you achieve the highest grades and turn out as one of the outliers in your class? Sometimes, the answer to these questions is as simple as ABC. But we often miss it, even when it is right before our faces. Getting to become the best in your class is predictable. Why? Because most of the grading systems are cumulative of essays and academic papers. So, it only makes sense to leverage these papers to ride high with your professors. How do you go about this? Sometimes, you might not have the necessary skill sets to leverage your papers. But should you give up nonetheless? No. The solution is right at your fingertips. Many custom writing services online are up to the task of taking your essays from where they are to where you want them to be. And they are always ready to serve you with a high level of discretionary service. Thus, we have carefully curated this list of TOP 8 online custom writing services. 99Papers - the best custom essay writing service. PaperHelp - #1 custom research paper writing provider. EssayBox - Top rated custom dissertation writing company. SpeedyPaper - the best custom term paper writers to hire. EssayPro - the cheapest custom writing service. Ivory Research - custom essay writing/editing service from UK. Studdit - #1 custom thesis company to buy it online. PaperCoach - professional college paper writers. And we chose these specific services based on the myriads of positive feedback from their clients, their promptness to deliver student essays, excellence in written content, the quality of their writers, and the stellar nature of their customer support. Are you ready to read more detailed reviews of each company? Here they are below. 8 Best Custom Writing Services #1. 99Papers 99Papers is the best custom essay writing service online for various reasons. For starters, their writers are highly qualified, experienced professionals with expertise in various topics. They have a team of experts from various backgrounds and disciplines who can provide quality content that satisfies your custom essay writing service needs. Furthermore, if you are wondering how safe it is to hire them, 99Papers has cutting-edge security protocols to protect customer data and guarantee privacy. Payment methods are also encrypted to ensure that transactions remain safe and secure at all times. This means that you can be rest assured knowing that your financial information will not be compromised or leaked when you buy an essay online through this service. Also, 99Papers provides excellent customer service with chat support 24/7. Whether you have questions about their orders or need help navigating the website, they can get immediate assistance from friendly representatives who will do everything possible to meet your needs quickly and effectively. This ascertains peace of mind while ordering essays online, especially because you know that you have reliable people working on your behalf to take care of any issues that may arise throughout the process. In addition, this custom essay writing service offers you highly competitive rates for their services compared to other providers in the market today. With just $9.95, you can access all the goodies they offer. This means more bang for your buck when it comes time to order an essay from this provider! With discounted prices on original content tailored specifically for each of your project requirements, there is no better option than 99Papers for you as a student seeking quality work but also wanting a great deal at the same time! And to cap it all up, all assignments created by 99Paper's writers come with free revisions included. This is remarkable. So, you and many students worldwide can be assured knowing that you will get what you want even after buying your essays online through this custom essay writing service's website! With unlimited revisions available just in case something isn't quite perfect – or if changes need to be made after feedback – you always receive top-notch results when placing orders with them, no matter what subject matter it covers or how complex its instructions may be! So, whether you are in high school or are presently writing your dissertation as a Ph.D. student, this service can tend to all of your academic writing needs. So, if you are looking for the best custom essay writing services available online today, that is, those who provide high-quality written work at affordable rates backed up by unbeatable customer care policies and free revisions, then make sure you check out 99Papers! #2. PaperHelp PaperHelp is another name for the best custom research paper writing service online because it provides superior quality papers and offers great value for money. PaperHelp has a team of highly skilled writers who understand the needs of their customers, ensuring that each paper is written to the highest possible standard. The company also has an extensive editing process that guarantees that even minor grammatical and intellectual property-related mistakes are detected and corrected. Furthermore, PaperHelp offers an impressive variety of services, ranging from writing essays to even creating presentations and research papers. They have many positive online reviews and students flocking to their website. The writers at this write my essay company take pride in their work and always strive to exceed your expectations by providing well-structured literature with correct referencing, useful inferences from facts, clear arguments, and clever solutions. The company's experienced editorial team reviews every paper before releasing it to customers to make sure they receive flawless content with accurate grammar, spelling, punctuation, and style usage. In addition, the editors check for originality by scanning every piece of work through reliable plagiarism detection software before submitting it to clients. This helps ensure that all customers get unique content without any traces of plagiarism or duplication. Apart from complete professionalism in writing tasks, PaperHelp also provides plenty of discounts and other benefits, such as free revisions within a specified time frame if requested by clients. They also provide you with 24/7 customer support via email or telephone, so you are kept abreast of the progress of your work. This ensures maximum satisfaction for students. PaperHelp's payments are secure, too, with several payment options available, like PayPal, Visa, MasterCard, etc. And this is fair in the “write my research paper” industry. With just only $10 per page, you get beautifully written original content just for you. Furthermore, there is an additional bonus program where regular customers can earn points depending on how much they order which can later be used towards discounts or free pages. #3. EssayBox EssayBox is one of the best custom dissertation writing services online because it offers a variety of features that make it stand out from other services. First and foremost, EssayBox provides high-quality dissertations and theses written by professional writers who have extensive knowledge in their respective academic fields. Papers they deliver are always relevant, well-researched, and tailored to meet your specific requirements as a student using their services. Moreover, EssayBox has an impressive customer service team that is always available to answer any questions and resolve any issues that may arise. They also offer free revisions as part of their service, so you can be certain that you will get what you asked for. In addition to quality and customer service, this custom dissertation writing service offers unbeatable prices compared to other online dissertation writing services. EssayBox's service costs $10 a page for high school dissertations and $28 for a Ph.D. The company even has affordable packages for those who require multiple papers or long-term projects done regularly. These special discounts help customers save money while getting quality work done quickly and efficiently. Furthermore, all payments are secured with 256-bit SSL encryption technology, so you, as a client, can be sure that your data is safe whenever you use this service to buy dissertations online. Last but not least, there are several guarantees provided by EssayBox when ordering a dissertation from them, including timely delivery before the specified deadline; total privacy & confidentiality; 100% original content & no plagiarism; unlimited revisions until satisfaction; money-back guarantee if not satisfied with results; 24/7 customer support & much more! This makes their service extremely reliable as it allows you a great deal of peace of mind knowing that you will receive what you asked for in the timeframe agreed upon beforehand without having to worry about any hidden charges or unpleasant surprises later on down the line. All in all, these factors make EssayBox one of the best custom dissertation writing services online! #4. SpeedyPaper SpeedyPaper is an online custom term paper writing service that takes pride in providing the best customer service and the highest quality papers. Established in 2020, SpeedyPaper aims to be a leader in the industry by providing students with dependable services and improved convenience. With more than 100k satisfied customers, SpeedyPaper has cemented itself as one of the best online custom term paper writing services. This custom term paper writing service has a wide range of services that are tailored to meet every student's needs: from simple term papers of a high schooler to difficult dissertations of Master’s students, their team of professional writers can handle any task. They guarantee 100% original content for every project, no matter how complex or urgent it may be; their 24/7 customer support team is always available for assistance and guidance when needed; they also offer editing and proofreading services to make sure your work is perfect before submission. Moreover, SpeedyPaper's intuitive website makes it easy to place orders with just a few clicks. That is, there is no need to waste time filling out long forms or struggling with confusing menus. Thus, their user-friendly interface ensures you can navigate quickly and easily between functions like selecting a writer, tracking progress on your order, contacting customer support if needed, etc. Plus, they have several secure payment methods, so you can rest assured that your money and information are safe at all times! In addition to the preceding benefits, SpeedyPaper offers many exciting discounts and rewards that give students even more bull for their buck! For example, it has an excellent loyalty program where loyal customers get rewarded after making each purchase – including free revisions/edits and additional discounts on future orders! These features have made many students choose Speedy Paper over competitors due to its affordability while still guaranteeing high-quality results on time! Overall, there are numerous reasons why many consider SpeedyPaper one of the top custom term paper writing service providers online today: it provides superior customer service along with top-notch written works created by knowledgeable professionals within tight deadlines; it offers competitive pricing structures along with lots of exciting rewards & discounts; most importantly its user-friendly interface allows easy navigation & ordering process which ultimately leads towards improved efficiency & greater satisfaction among users! #5. EssayPro EssayPro is one of the cheapest custom writing services online because it provides its customers various services. From general topics to more specialized areas, EssayPro offers an extensive selection of writing services that can be tailored to fit the needs of each customer. With experienced and qualified writers on staff, customers have access to a team that understands their academic needs and can help them craft high-quality essays or other written work. In addition, EssayPro offers competitive pricing for all its services. Customers who use the service for basic tasks such as editing or proofreading will find that prices are quite reasonable compared to other custom writing websites. This makes it easy for students on tight budgets to complete their papers without worrying about the cost. Furthermore, discounts are available from time to time so students can get additional savings when ordering from them. The website also has an excellent user interface, making it quick and easy for customers to navigate the various sections available and place orders anytime. Additionally, they offer multiple payment options, including credit card payments encrypted with secure technology, so customers don't need to worry about their information being compromised when making purchases with them online. Moreover, their customer support team is always available 24/7 by phone or email in case any issues arise with orders or payment methods used on-site, which further emphasizes how committed they are to providing a top-quality experience for all their customers no matter what time it may be during days throughout the year. They also have numerous positive reviews from past customers across different review sites, further solidifying how reliable and well-organized these guys are when delivering high-quality custom essay writing services online! #6. Ivory Research Ivory Research is one of the best custom essay writing services available online in the United Kingdom. It provides a range of great features that make it stand out from the competition. Firstly, their writers are highly experienced and knowledgeable in their fields, ensuring that essays are written to a high standard. The writers also have access to an extensive database of resources which enables them to research any topic thoroughly, ensuring that your essay will be well-informed and current. In addition, Ivory Research's website is extremely easy to use and navigate. You can easily search for what you need or browse through categories such as academic essays or dissertations. The interface is intuitive, so you don't have to waste time getting used to how everything works. Furthermore, customers can track their orders so they know exactly when they should expect results – this allows them peace of mind knowing when their work will be received by Ivory Research's team of professional writers. Moreover, all orders placed on Ivory Research come with a satisfaction guarantee – meaning if there are any issues with the essay you receive then the company will either revise it until it meets your requirements or provide a refund in full if needed. This ensures customers have trust in using Ivory Researches services as they know they won’t be left disappointed at the end of it all! Perhaps most importantly though is that ordering an essay from Ivory Research means accessing 24/7 customer service support that runs 365 days a year – this means you can quickly resolve any queries without having to wait for long periods for online help or emails to be answered (which can sometimes take days). In conclusion, there is no doubt why Ivory Research has become one of the most popular custom essay writing services available online today; its experienced writers combined with an easy navigation website makes it ideal for students looking for quick results and excellent quality work -all backed up by 24/7 customer service support providing peace-of-mind assurance throughout every stage! #7. Studdit Studdit is one of the best custom thesis writing services available online. Studdit offers a wide range of services to help students with their academic papers, including thesis writing and editing, proofreading, formatting, and more. With its wide array of features and benefits, Studdit has become a trusted name in the industry for providing quality custom paper writing services that meet the needs of any student. One of the primary advantages that create Studdit stand out from other thesis writing services is its team of experienced writers who are experts in their respective fields. Each writer understands how to craft an engaging thesis tailored to your assignment's specifications and requirements. Plus, most writers have gone through rigorous tests to ensure they have the knowledge to deliver accurate results on any given topic or subject matter. This way, you can be sure that your paper will be well-written and error-free each time you use Studdit's service. Aside from offering top-notch writers for your assignments, another great thing about using Studdit is its user-friendly interface, which makes it easier for customers to place orders quickly without any technical difficulties or delays. The system also allows customers to track their order progress, so they know when it's ready for submission without worrying about deadlines or rushing through complex editing processes prior submission date. Moreover, customers can communicate directly with their assigned writer to provide clarifications regarding their instructions as needed - assuring them that all requirements will be met perfectly before submitting an assignment. Finally, what makes Studdit even more beneficial than other providers is its reasonable pricing structure which lets students save money while still getting quality papers on time - perfect if you need help but don't want to break the bank! And if all these features weren't enough already, then there's also a money-back guarantee should anything go wrong with your order - allowing customers peace of mind knowing they're protected against bad experiences while using this excellent service! It's easy to see why so many people choose Studdit as one of their go-to custom thesis writing services online – it provides everything needed for successful academic paper completion at a great price! #8. PaperCoach PaperCoach is another notable name among the best custom college paper writing services online. And this is largely due to the quality of their writing, customer service, and reasonable prices. Their writers are all highly qualified and knowledgeable about a wide variety of topics. They will take your project from concept to completion, providing you with high-quality ideas and content that meets your unique order specifications. Additionally, they guarantee 100% satisfaction by editing and proofreading everything they write for you until it meets your expectations. The customer service team at PaperCoach is extremely helpful in addressing any questions or concerns you may have before, during, or after using their services. They are available 24 hours a day to assist with what you need from experience. In addition, they offer assistance in selecting the right writer for your project as well as helping guide them throughout the entire process if needed. PaperCoach also offers some of the most competitive prices of $7.99 on custom essay writing services online today without sacrificing quality or customer service standards. All projects are backed by a money-back guarantee which ensures that you are completely satisfied with what you receive from PaperCoach every time you use their services. Furthermore, discounts are frequently offered so students can save even more on their orders! Overall, PaperCoach provides top-notch custom essay writing services online at an unbeatable value for money compared to other providers available today. In addition, customers can rest assured knowing that their projects will be handled professionally and delivered on time with no surprises along the way! The combination of highly qualified writers, exceptional customer service, and reasonable prices makes PaperCoach an excellent choice for anyone looking for a reliable custom essay provider! A little more about custom writing What is a custom writer? A custom writer is a professional who specializes in providing unique written content tailored to the needs of a specific client or student. They are responsible for creating original, engaging, and informative articles, blog posts, marketing materials, web copy, and other written content that speaks to their client's target audience. And in this case, they also write specific academic essays for students worldwide in different fields of human endeavor. Further, custom writers often have expertise in one or more particular topics or industries so that they can write compelling pieces about those topics. By understanding their client's goals and audience, custom writers can craft effective pieces that captivate readers and drive them to take action. In addition to writing from scratch, many custom writers also provide editing services such as proofreading or copy-editing existing work for better clarity and accuracy. Ultimately, working with a custom writer can help businesses create useful written content that resonates with their target market while saving time. And they also provide a student with a full-on excellent paper they need to get high grades with their professors. Is custom writing legit? Custom writing services are becoming increasingly popular among students who need help with their academic assignments. And rightly so. These services offer custom-made essays and papers at competitive prices, thus, allowing students to save time and energy when tackling their assignments. But is this approach legit? The answer is yes, as long as you choose a reliable service provider. Reputable companies offering custom writing will employ trained professionals with backgrounds in relevant fields of expertise. They also have a strict quality control system that ensures all content they produce meets the highest standards of academic excellence. In addition, they guarantee the authenticity of all their work by providing revisions upon request and using advanced plagiarism detection software to check for any signs of plagiarism before delivering the final product to clients. This ensures that your paper will be totally unique and one-of-a-kind for every order you place with them. Can you get caught using a custom writing service? A custom writing service is an excellent option for those needing help completing their paper. However, it is important to remember that you cannot get caught using such a service. And it is important to select a reputable provider who guarantees the anonymity and confidentiality of your order, as well as provides plagiarism-free content. Additionally, make sure the provider has a money-back guarantee in case of any issues with the order or the quality of work. Finally, keep your login information private at all times so that no one can track your activity on the website. Following these tips will ensure you remain anonymous when using custom writing services. How do I find a good custom writing service? Finding a good custom writing service these days can be tricky. But there are a few steps you can take to ensure you end up with an excellent product. First, research the options available in your area and read customer reviews. Be sure to research the policies of each provider and compare prices before making a decision. It's also important to ask questions if there is something you need help understanding. Also, look for services that offer discounts or free consultations as these could save you money in the long run. Finally, be sure that whatever service you choose provides writers with experience in your specific field; this will guarantee quality work tailored to your needs. With these tips, finding a great custom writing service should be easy! So, choose from the list of excellent services above. They will surely give you a great experience with so much discretion and trustworthiness! What is the best custom essay writing service? 99Papers is the best custom essay writing service available on the market today. It provides a secure and reliable platform for customers to order and receive essays quickly. In addition, 99Papers offers a wide range of essay topics, from high school essays to Ph.D. dissertations. And customers can also select from over 3,000 expert writers for their essay projects. Further, their customer service team is always available to answer any questions and provide assistance with ordering, payment processing, and delivery of essays. 99Papers also offers free revisions on all orders so that customers can be sure they are getting what they need in their writing. With its commitment to customer satisfaction and quality writing services, 99Papers is the go-to choice when it comes to custom writing services online. Where can I find the best custom research paper writers to hire? Finding the best research paper writers to hire can be a daunting task. However, you have PaperHelp to the rescue. PaperHelp is an online platform that helps you find the best custom research paper writers who are experienced and knowledgeable in their subject areas. This platform offers various writing services, such as editing, proofreading, and formatting. All their writers are native speakers with postgraduate degrees from renowned universities and have at least five years of writing experience. They also help you select the appropriate writer for your project based on their qualifications, expertise, and availability. In addition, all papers written by PaperHelp researchers are 100% unique, free from plagiarism, and tailored to meet your specific needs. If you're looking for top-notch professional research paper writers to hire, then PaperHelp is worth considering. How to buy a professional written custom dissertation? EssayBox is the premier online destination for students who want to purchase a professionally written custom dissertation. With an extensive network of writers worldwide, EssayBox can provide students with high-quality, original dissertations at reasonable prices. EssayBox's experienced writers are experts in their fields, with PhDs and Master's Degrees in various disciplines. They understand what it takes to write a successful dissertation - from the research and literature review stages to the conclusion stage. Best of all, they guarantee 100% satisfaction or your money back! So, if you're looking for a great way to complete your dissertation on time without compromising on quality, look no further than EssayBox today! What is the cheapest custom writing service online? EssayPro is an online custom writing service that provides high-quality, affordable content for students of all levels. It specializes in writing essays and research papers for college, university, and postgraduate students. The writers are experts in their field and have access to a wide range of resources to ensure the best quality work. They also offer editing services so your essay or paper can be polished perfectly before submission. The best part about using EssayPro is that it's significantly cheaper than other custom writing services online due to its low prices per page. For example, a single page written by a professional writer from EssayPro will cost you only $12, which is incredibly budget-friendly compared to other services, which charge $20 or more per page for the same work. Moreover, there are discounts available for bulk orders, making it even more economical than traditional custom writing services. And a few words at the end... Now you see that scaling high in your essays is as easy as squeezing a ball of cotton wool. How easier can it be to have such remarkable services at your beck and call for high-standard essays and papers when you need them? The days of suffering in silence due to your inadequacies with the right command of the English language have come to an end. You do not have to be an expert in the lingua to get stellar grades on your papers. You can outsource them to many of these online custom writing services. They are well-armed with everything necessary to give you a fresh and grammatically-correct essay. And yes, if you think you might fall into trouble because you patronize them, the above article has cleared your doubts. You have nothing to be afraid of. These write-my-essay platforms are the best at what they do. Not only because they churn out the best content for you to score high grades in school but also because they are discreet in managing your information. And they have a high standard for privacy policies when it comes to their clientele's details. So, guess what? You are fully covered! So, what are you waiting for? Reach out to any of them today! Contact Details Robert Claus robert.claus@best-essay-services.com

December 27, 2022 07:49 PM Eastern Standard Time

Holiday Season Winner? This Electric Toothbrush Maker Generated Record Sales In November And Is Appearing On Home Shopping Channel TSC

Bruush Oral Care Inc.

Learn more about Brüush by downloading the latest research report here According to a survey by SurveyMonkey, about 32% of people said they spent $100-300 on holiday gifts, 29% said they spent less than $100, and 7% said they spent over $1000. The survey paints a perfect picture of the importance people attach to holiday gifts. As yuletide draws closer, these gifts are bound to be an integral part of the shopping list of customers who throng some of America’s biggest shopping outlets, such as Target Corporation (NYSE: TGT), Best Buy Co Inc. (NYSE: BBY), Amazon.com Inc. (NASDAQ: AMZN), Walmart Inc. (NYSE: WMT), Macy’s Inc. (NYSE: M) and Wayfair Inc. (NYSE: W). Interest in these holiday gifts does have a positive ripple effect on stocks of these shopping outlets, including companies like Signet Jewelers Ltd. (NYSE: SIG) and Apple Inc. (NASDAQ: AAPL), which produce holiday items such as jewelry and gadgets. The time of the year does often bring growth to sellers of gifts, and one company just saw record sales this November. The talk of stocks that perform during the festivities and choosing the perfect Christmas gift could bring to mind another company, Brüush Oral Care Inc. (NASDAQ: BRSH), a modern electric toothbrush brand looking to disrupt the oral care market. Perfect Gift This Holiday Season? What could be getting this company some attention is a recent report that it recorded more than $500,000 in revenues in November, representing year-over-year growth of over 50%. The impressive sales resulted in November 2022 being the best month in the company’s history. For many, the news may not come as a surprise considering the fact that Brüush recently revealed that its beautifully designed one-of-a-kind electric toothbrush has received more than 90% five-star review ratings with less than a 1% return rate. The electric toothbrush is built with the highest-quality Sonicare technology, four-week battery life and best-in-class prices. The company says it is determined to make the move from manual to electric a no-brainer, backed by a brush head refill subscription plan. The plan includes three new brush heads for $18 ($6 per brush head) with free shipping every six months. Exciting Times To Brüush? Currently, the company says it has over 35,000 active subscriptions in its brush head refill program, representing a 25% increase during the four-month period since going public in August 2022. “We are obviously excited about our growth since the IPO in August and that November was a record month for us. Our electric toothbrush makes a great gift, so we expect strong sales to continue through the holiday season,” Aneil Manhas, Founder and CEO of Brüush, said. The company also recently announced that it’s participation in a one-day sales campaign on the home shopping channel, Today’s Shopping Choice (“TSC”), on Friday December 16, 2022. “This will be the Company’s second appearance on the home shopping channel, with their first appearance having taken place in September. TSC is Canada’s only nationally televised shop-from-home service, reaching into over 7 million households. The Brüush electric toothbrush will be featured on TSC during three segments on Friday, December 16, which can be viewed on the TSC website ( https://tsc.ca ) and will occur at 9.30am, 1.30pm and 5.30pm (Eastern Standard Time).” About Bruush Oral Care Inc. Bruush Oral Care Inc. is on a mission to inspire confidence through brighter smiles and better oral health. Founded in 2018, Brüush is an oral care company that is disrupting the space by reducing the barriers between consumers and access to premium oral care products. The Company is an e-commerce business with a product portfolio that currently consists of a sonic-powered electric toothbrush kit and brush head refills. Brüush has developed a product to make upgrading to an electric brush appealing with three core priorities in mind: (i) a high-quality electric toothbrush at a more affordable price than a comparable electric toothbrush from the competition; (ii) a sleek, countertop-friendly design; and (iii) a convenient brush head refill subscription program that eliminates the frustrating experience of purchasing replacement brush heads at the grocery/drug store. The Company is rooted in building a brand that creates relevant experiences and content, with the goal of becoming the go-to oral care brand for millennials and Generation Z.For more information on Bruush Oral Care Inc visit https://bruush.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details TraDigital IR - Colette Eymontt colette@tradigitalir.com Company Website http://www.tradigitalir.com

December 27, 2022 08:00 AM Eastern Standard Time

Recent Report Shows That Extracellular Vesicles Might Also Be Key To Stopping COVID, Colds, And Other Nasal Viruses

Organicell Regenerative Medicine, Inc.

To learn more about Organicell, download the latest research report here Organicell Regenerative Medicine, Inc. (OTCQB: OCEL) is a pioneer in the Extracellular Vesicle (EV) space. They have already been developing exosome-based drug candidates for the treatment and prevention of COVID-19, Long COVID, Chronic Obstructive Pulmonary Disease (COPD), osteoarthritis, and other conditions. Its flagship product, Zofin™, is in human clinical trials. Since being FDA approved for an expanded access trial, the company has also treated 18 people with the exosome-based therapy and the results are promising with patients showing reduced inflammation and improved lung function. New Information Linking Exosomes and the Common Cold However, a possible new reason for companies like Organicell to get excited about EVs has recently been uncovered by researchers at Harvard University. “In what researchers are calling a scientific breakthrough, scientists behind a new study may have found the biological reason we get more respiratory illnesses in winter. It turns out the cold air itself damages the immune response occurring in the nose.” It seems that EVs have an absolutely crucial role in preventing germs from effectively entering and getting a foothold in the body through the nose. The body creates and uses EVs to mop up and get rid of harmful agents, but this becomes seemingly far more difficult when the temperature outside gets extra low. “In fact, that little bit of coldness in the tip of the nose was enough to take nearly 42% of the extracellular vesicles out of the fight…” One of the researchers, Dr. Benjamin Bleier, “expects to see the development of topical nasal medications that build upon this scientific revelation. These new pharmaceuticals will ‘essentially fool the nose into thinking it has just seen a virus,’ he said.” The Emerging Research On Exosomes Is Filled With Promise, But Still New While often confused with stem cells, exosomes are not cells. They are the smallest of all Extracellular Vesicles (EVs) – the various particles cells secrete to send messages and materials to each other. EVs are how cells tell each other to reproduce, differentiate into specific cells, repair, and so on. It’s also how cells pass along proteins, lipids, DNA, RNA, and other materials that the receiving cell might need to carry out those functions. EVs may have the potential to reduce inflammation, repair damaged tissue, and otherwise help cells regenerate and heal. Their ability to carry cargo to a cell has also attracted interest from biopharmaceutical developers who are looking into using EVs as a delivery mechanism for therapeutics. If these developers can engineer EVs that carry a specific drug to specific cells – like delivering chemotherapeutic agents to tumor cells – they could create more targeted treatments with fewer adverse reactions. Biotech companies are working on creating the technology necessary to reliably engineer exosomes to create potent and highly targeted treatments. This field of study is still emerging and there is a lot that researchers still don’t yet know about EVs. A lot of the most promising data to come out about these messenger particles is from animal and cell culture studies. So a major hurdle the research still needs to overcome is whether those exciting findings will translate to human studies. Organicell is among the companies to have already begun human trials for an exosome therapy. Zofin TM, its lead drug candidate, is being developed as a potential treatment for COVID, Long COVID, COPD, and osteoarthritis. Does all this mean even bigger opportunities for treatments and products for companies like Organicell? Learn more about Organicell’s research and products here. Organicell Regenerative Medicine, Inc. (OTCQB:OCEL) is a clinical-stage biopharmaceutical company principally focusing on the development of innovative biological therapeutics for the treatment of degenerative diseases and the provision of other related services. The Company's proprietary products are derived from perinatal sources and manufactured to retain the naturally occurring exosomes, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent. Certain of the statements contained in this press release should be considered forward-looking statements within the meaning of the Securities Act of 1933, as amended (the "Securities Act"), the Securities Exchange Act of 1934, as amended (the "Exchange Act"), and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are often identified by the use of forward-looking terminology such as "will", "believes", "expects", "potential", or similar expressions, involving known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, they do involve assumptions, risks and uncertainties, and these expectations may prove to be incorrect. We remind you that actual results could vary dramatically as a result of known and unknown risks and uncertainties, including but not limited to: potential issues related to our financial condition, competition, the ability to retain key personnel, product safety, efficacy and acceptance, the commercial success of any new products or technologies, success of clinical programs, ability to retain key customers, our inability to expand sales and distribution channels, legislation or regulations affecting our operations including product pricing, reimbursement or access, the ability to protect our patents and other intellectual property both domestically and internationally, and other known and unknown risks and uncertainties, including the risk factors discussed in the Company's periodic reports that are filed with the SEC and available on the SEC's website (http://www.sec.gov). You are cautioned not to place undue reliance on these forward-looking statements. All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these risk factors. Specific information included in this press release may change over time and may or may not be accurate after the date of the release. Organicell has no intention and specifically disclaims any duty to update the information in this press release. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Organicell Investor Relations IR@organicell.com Company Website https://organicell.com/

December 27, 2022 08:00 AM Eastern Standard Time

Insider Buying: Sunshine Biopharma Inc. (NASDAQ: SBFM) Chief Financial Officer Purchases Shares

Sunshine Biopharma Inc.

To learn more about Sunshine Biopharma, download the latest research report here Sunshine Biopharma Inc. (NASDAQ: SBFM) is a fully integrated pharmaceutical company offering and researching life-saving medicines in a wide variety of therapeutic areas, including oncology and antivirals. On November 30th, 2022, Sunshine Biopharma’s chief financial officer (CFO) Camille Sebaaly purchased 30,000 shares at $0.7635/share for a total of $23,000. The Canadian-based company is heavily focused on eradicating the virally-driven Covid-19 pandemic. While its expansion has seemingly calmed down in the West, the SARS-CoV-2 virus has resurged in China, triggering state-sanctioned quarantine mandates. Only months ago, Sunshine Biopharma Inc. announced a $19.5 million private placement priced at the market, a funding round aimed to help the Sunshine Biopharma team achieve its mission of eradicating the pandemic and creating life-saving anti-cancer treatments. An Overview Of Sunshine Biopharma Aside from insider buying ( including another recent purchase by Sebaaly in June of 25,000 shares at $1.22 per share for a total of $30,500), Sunshine Biopharma has seen a number of potentially constructive developments in its business. These include: Pioneering a novel Covid-19 treatment method, called SBFM-PL4, that reportedly targets a different part of the virus than other treatments. Creating a flagship anticancer compound, Adva-27a, that, unlike other antitumor drugs, can destroy multi-drug-resistant cancer cells. Filing a provisional patent application in the United States about the company’s mRNA cancer treatment results, which were shown to destroy cancer cells grown in culture. Developing nutritional supplements, like Essential 9™, for sale in Canada and the U.S. on Amazon The company also completed an acquisition of Nora Pharma, a Canadian pharmaceutical company offering generic and specialty drugs across the country, which adds $10.7 million in revenue for 2022. With a focus on both oncology and antiviral drugs, Sunshine Biopharma is placing itself within two fast-growing markets. According to Bloomberg, the anti-viral drug market size is expected to reach $50 billion in 2030, and the oncology market is expected to be worth around $536 billion by 2029. Click here for more on Sunshine Biopharma. In addition to working with the University of Arizona on the development of a treatment for COVID-19, Sunshine Biopharma is engaged in the development Adva-27a, a unique anticancer compound. Tests conducted to date have demonstrated the effectiveness of Adva-27a at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells, Small-Cell Lung Cancer cells, Breast Cancer cells, and Uterine Sarcoma cells. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Montreal, Canada. Sunshine Biopharma is also engaged in the development of a novel anticancer mRNA called K1.1. The data collected to date have shown that K1.1 mRNA is capable of destroying cancer cells in vitro including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). Studies using non-transformed (normal) human cells (HMEC) have shown that K1.1 mRNA had little or no cytotoxic effects. K1.1 mRNA is readily adaptable for delivery into patients using the proven mRNA vaccine technology. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Christine Petraglia - TraDigital IR +1 917-633-8980 investors@sunshinebiopharma.com Company Website https://sunshinebiopharma.com/

December 27, 2022 08:00 AM Eastern Standard Time

70% Of Americans Don’t Floss - This Company Aims To Change That With Its New Engineering Approach

Instafloss

Interested in investing in Instafloss’s campaign? Click here to get started. Oral Care Is More Important Than You Think While it can be easy to neglect your oral health, an unhealthy mouth can be a precursor for an unhealthy body. The mouth is filled with both good and bad bacteria, and when the mouth, teeth, and gums are poorly taken care of, bad bacteria take over. Because the mouth is the entry point for the respiratory and digestive systems, these bacteria can then spread even further and cause disease. Individuals with poor oral health have higher risks of cardiovascular disease, heart attacks, pneumonia, and other ailments. Take cardiovascular disease - inflammation in the gums will slowly travel down the body to the arteries and increased plaque build-up can cause heart attacks. Despite these high risks, only 58% of Americans see a dentist as least once a year. Nearly 1 million Americans visit the emergency room each year because of dental pain, according to a Pew study. Oral health, or rather the lack of oral health, can have catastrophic effects on the body. The long-lasting effects of poor oral care are why it is so important for individuals to have a strong oral care routine and tools at home to maintain a healthy mouth, teeth, and gums. Instafloss Has Engineered What Could Be A Perfect Solution Currently, there are two options available on the market when it comes to flossing: standard floss and manual 1-jet water flossing. Both options can be time-consuming, cumbersome and painful and as a result, 70% of Americans do not floss. Furthermore, individuals who do floss often do it ineffectively. Individuals deserve better options for flossing that promote oral health. That’s why Instafloss developed its multi-jet water flosser. Instafloss’s design aims all the jets for the user at the correct 90-degree angle, ensuring that the teeth and gums are fully covered. It only takes 10 seconds to sweep across the teeth and Instafloss uses a patented H-design mouthpiece that fits over the top and bottom teeth. Instafloss is able to clean between your teeth, underneath your gum line, and all the way around each tooth for maximum coverage. Water flossing could be the way of the future. When compared to string flossing, water flossing is 151% as effective at reducing gingivitis, 129% as effective at removing plaque, and 200% as effective at reducing bleeding, according to research cited on the Instafloss website. Instafloss is currently hosting a raise on Republic to propel the company forward. The company has over $2.5 million in pre-orders with another 41,000 individuals on an email waitlist. To date, they have raised over $950k in equity capital. With 5 years of testing and granted utility patents, the company is ready to become the next big thing in oral care. Click here to read more about Instafloss’s raise and how to invest. Instafloss is the world’s first 10 second floss. It is painless, effective, and fast — removing obstacles to oral health. Contact Details Eli Packouz eli@instafloss.com Company Website https://instafloss.com/

December 27, 2022 08:00 AM Eastern Standard Time

Precigen’s Overnight Cell Manufacturing Technology Could Offer Advanced AML Patients The Option Of Promising CAR-T Therapy

Precigen, Inc.

Acute myeloid leukemia (AML) is among the most common types of leukemia in adults. The term leukemia refers to cancers of the bone marrow and blood cells. Doctors refer to AML as “acute” because the condition is known to progress rapidly. The five-year survival rate for patients with AML is as low as 5%, leading to approximately 11,000 deaths annually in the US. Each year sees 20,000 newly diagnosed cases of AML and, after initial treatments, roughly 50% relapse with a very poor prognosis. Precigen Inc. (NASDAQ: PGEN), a biopharmaceutical company specializing in the development of novel gene and cell therapies, has developed a ground-breaking technology that enables the treatment of AML using targeted CAR-T therapy administered overnight right at the facility where a patient is being treated. In some cancers, such as advanced AML, even a day’s delay in treatment could make a difference in survival. The main treatment for most types of AML is currently chemotherapy, which has been the mainstay of treatment for various types of cancers for decades. But over the past several years, the U.S. Food and Drug Administration (FDA) has approved new categories of cancer medicines – among them CAR-T – which are transforming the treatment picture of certain cancers effectively, and in some cases helping to stave off cancer for many years. CAR-T Therapy Developed By Precigen Could Potentially Be A Promising First In The Treatment Of AML AML progresses very rapidly, making it essential to treat it as quickly as possible. Because of this, autologous CAR-T therapy, which usually takes 3-4 weeks to manufacture for each patient, has not been successful in treating patients with advanced AML. The current process for making autologous CAR-T therapy involves multiple, time-consuming and costly steps that include drawing patient blood, transporting it to a central manufacturing facility, transfecting the patient’s T cells with a lentivirus for antigen targeting, and expanding the cells for weeks in the lab before shipping the therapy back for infusion into the patient. T cells, a key component of the immune system, help the body fight infection and tumors. In contrast, Precigen’s technology condenses this time-consuming process into overnight manufacturing using the patient's own cells to make its UltraCAR-T cells. This is made possible by using the company’s patented UltraPorator ®, a custom manufacturing device, designed for decentralized use to enable UltraCAR-T to be made and administered in any hospital where the patient is being treated. Precigen is conducting a Phase 1b clinical trial of its PRGN-3006 UltraCAR-T in patients with advanced AML who have failed multiple prior therapies. The company released encouraging clinical data last year, raising hopes that PRGN-3006 could prove to be a significant new treatment choice for relapsed or refractory AML patients who have run out of other options. Updated data presented earlier this month at the 64 th Annual Meeting and Exposition of the American Society of Hematology showed that a single infusion of UltraCAR-T cells following lymphodepletion demonstrated robust expansion and persistence in blood and bone marrow and resulted in a 27 percent objective response rate (ORR) is heavily pre-treated r/r AML patients. David A. Sallman, MD, Assistant Member in the Department of Malignant Hematology at the H. Lee Moffit Cancer Center and Research Institute, and a lead investigator for the PRGN-3006 clinical trial, said a 27 percent ORR in this patient population, which has limited treatment options, is a significant result. He reported PRGN-3006 has an excellent safety profile with no drug-limiting toxicities observed to date, and noted that a patient who received PRGN-3006 following allo-HSCT has responded to treatment for more than 18 months. The success of its clinical trials could establish the viability of reducing the processing time of autologous CAR-T therapy for AML from weeks to overnight – a time advantage that could save lives at a significantly lower cost. Combining The Best Of Autologous And Allogenic CAR-T technology For Optimum Results? There are two forms of CAR-T (chimeric antigen receptor T cell) technology. One is autologous (custom-made for each patient with the patient's own cells), and the other is allogenic (made with donor-sourced cells and packaged as an off-the-shelf product). The current market for autologous CAR-T therapy comprises key players including Gilead Sciences, Inc. (NASDAQ: GILD), Bristol-Myers Squibb Co. (NYSE: BMY), Novartis AG (SWX: NOVN) and Johnson & Johnson (NYSE: JNJ). Although autologous CAR-T has a record of good outcomes, its high cost and prolonged time to manufacture (up to 28 days) have been seen as major drawbacks. Clinical trials of off-the-shelf allogenic CAR-T have been met with limited success so far. The drawbacks of allogenic CAR-T include reduced durability of response and potential issues relating to the rejection of the donated graft by the patient (graft vs host disease), which could prove to be treatment-limiting and outweigh the potential cost and convenience benefits of this type of treatment. Companies developing allogeneic CAR-T include Allogene Therapeutics Inc. (NASDAQ: ALLO), Crispr Therapeutics AG (NASDAQ: CRSP), Editas Medicine Inc. (NASDAQ: EDIT) and Caribou Biosciences Inc. (NASDAQ: CRBU). The Precigen approach seeks to combine the efficacy and safety of autologous CAR-T with the potentially lower cost and convenience of allogenic CAR-T. Precigen’s UltraCAR-T is a platform technology, potentially adaptable to the treatment of many different cancers, in both liquid and solid tumors. Other UltraCAR-T candidates in development include PRGN-3005 for recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer, and PRGN-3007 for treating a variety of cancers, including chronic lymphocytic leukemia, mantle cell leukemia, acute lymphocytic leukemia and triple-negative breast cancer. The company also reports that PRGN-3006 UltraCAR-T has demonstrated a favorable safety profile to date with no dose-limiting toxicities or neurotoxicity. PRGN-3006 has also received orphan drug designation and fast track status from the FDA. "We are very pleased to receive the FDA's Fast Track designation, which facilitates development and expedites the review process of drugs that address serious conditions and high unmet medical needs," says Helen Sabzevari, PhD, President and CEO of Precigen. Dr. Sabzevari added, "AML is a rapidly progressing disease with a very poor prognosis. The Fast Track designation will help facilitate the timely development of this program and we look forward to working closely with the FDA to potentially bring this new and highly differentiated overnight UltraCAR-T therapy to patients." Click here for more information about Precigen, Inc. (PGEN) This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Photo by National Cancer Institute on Unsplash Precigen: Advancing Medicine with Precision™Precigen (Nasdaq: PGEN) is a dedicated discovery and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. Our technologiesenable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an innovation engine progressing a preclinical and clinical pipeline of well-differentiated therapies toward clinical proof-of-concept and commercialization. For more information about Precigen, visit www.precigen.com or follow us on Twitter @Precigen, LinkedIn or YouTube. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Some of the statements made in this press release are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio of therapies, and in particular its CAR-T and AdenoVerse therapies. Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the Securities and Exchange Commission. Contact Details Steven M. Harasym sharasym@precigen.com Company Website https://precigen.com/

December 27, 2022 08:00 AM Eastern Standard Time

Multiple Shots On Goal: Can-Fite’s Late-Stage Clinical Pipeline Hits Positive Results

Can-Fite Biopharma

Multiple countries are approving Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) ’s Namodenoson for compassionate use in patients with advanced liver cancer. These countries, including Romania and Israel, seem to have acknowledged Namodenoson’s high efficacy and good safety record with anti-inflammatory and anti-cancer effects — in line with Phase II and Phase III studies conducted by the company. Namodenoson is an oral small molecule drug generically known as Cl-IB-MECA (2-chloro-N6-(3-iodobenzyl)-adenosine-5’- N-methyl-uronamide), a highly specific and selective agonist at the A3 adenosine receptor (A3AR). According to Can-Fite, the drug has a potent anti-cancer effect, particularly against hepatocellular carcinoma, and anti-inflammatory activity demonstrated in pre-clinical animal models of liver inflammation and in a Phase IIa NASH study. Interestingly, Namodenoson is not the only drug in the company’s pipeline that seems to be grabbing a lot of attention. Can-Fite is also conducting studies for Piclidenoson for treating psoriasis and CF602 for treating erectile dysfunction. Can-Fite seems to have carved a niche for itself as an advanced clinical-stage drug development company with a platform technology designed to address multi-billion-dollar markets in the treatment of cancer, liver, and inflammatory disease. Multiple Shots On Goal The company’s lead drug candidate, Piclidenoson, recently reported topline results in a Phase III trial for psoriasis. Namodenoson is being evaluated in a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH), and Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer, is open for enrollment. The drug has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second-line treatment for HCC by the U.S. Food and Drug Administration. Can-Fite says Namodenoson has shown proof of concept to potentially treat other cancers, including colon, prostate, and melanoma. The company’s third drug candidate, CF602, reports suggest, has also shown efficacy in treating erectile dysfunction. These drugs, according to Can-Fite, have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. Late-Stage Clinical Development Pipeline The company’s late-stage clinical pipeline seems to be ticking all the right boxes. For example, Can-Fite recently reported that if the Phase III pivotal (registration) study for liver cancer meets its primary endpoint, then Namodenoson can be approved to treat it. The Phase III pivotal (registration) study for psoriasis, it added, is now being prepared based on successful results from the most recent Phase III study of Piclidenoson, which showed the drug is safe and effective. Lastly, the Phase IIb NASH study is now enrolling and treating patients, following a successful Phase IIa study. Clearance Of Cancer In Patients Treated With Namodenoson? On October 25, the company reported that a patient, a 61-year-old woman with hepatocellular carcinoma (HCC), the most common form of liver cancer, and moderate hepatic dysfunction Child-Pugh B (CPB7), participated in Can-Fite’s prior Phase II study. The patient was in the Namodenoson arm of the Phase II study and continued treatment with Namodenoson for five years under an Open Label Extension Program. Treatment is ongoing under a Compassionate Use Program established in Romania in August of 2022. This case report demonstrates that treatment with Namodenoson can lead to a complete and durable response in patients with HCC and CPB7. Current Out-Licensing Deals Can-Fite has out-licensed its drugs to companies such as Cipher Pharmaceuticals Inc. (TSE: CPH) (Canada), China Medical System Holdings (HKG: 0867) (China), Kyongbo Pharmaceutical Co Ltd. (KRX: 214390) (South Korea), Gebro Pharma (Spain, Austria, and Switzerland), and Ewopharma (Central Eastern Europe). The company has already received $20 million in upfront and milestone payments and expects $130 million in revenues based on regulatory and sales milestones. About Can-Fite BioPharma Ltd.Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CFBI) is an advanced clinical stage drug development Company with a platform technology that is designed to address multi-billion dollar markets in the treatment of cancer, liver, and inflammatory disease. The Company's lead drug candidate, Piclidenoson recently reported topline results in a Phase III trial for psoriasis. Can-Fite's liver drug, Namodenoson, is being evaluated in a Phase IIb trial for the treatment of non-alcoholic steatohepatitis (NASH), and enrollment is expected to commence in a Phase III trial for hepatocellular carcinoma (HCC), the most common form of liver cancer. Namodenoson has been granted Orphan Drug Designation in the U.S. and Europe and Fast Track Designation as a second line treatment for HCC by the U.S. Food and Drug Administration. Namodenoson has also shown proof of concept to potentially treat other cancers including colon, prostate, and melanoma. CF602, the Company's third drug candidate, has shown efficacy in the treatment of erectile dysfunction. These drugs have an excellent safety profile with experience in over 1,500 patients in clinical studies to date. For more information please visit: www.can-fite.com. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Forward-Looking StatementsThis press release may contain forward-looking statements, about Can-Fite’s expectations, beliefs or intentions regarding, among other things, its product development efforts, business, financial condition, results of operations, strategies or prospects. All statements in this communication, other than those relating to historical facts, are "forward looking statements". Forward-looking statements can be identified by the use of forward-looking words such as "believe," "expect," "intend," "plan," "may," "should" or "anticipate" or their negatives or other variations of these words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject to known and unknown risks, uncertainties and other factors that may cause Can-Fite’s actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results, performance or achievements to differ materially from those anticipated in these forward-looking statements include, among other things, our history of losses and needs for additional capital to fund our operations and our inability to obtain additional capital on acceptable terms, or at all; uncertainties of cash flows and inability to meet working capital needs; the initiation, timing, progress and results of our preclinical studies, clinical trials and other product candidate development efforts; our ability to advance our product candidates into clinical trials or to successfully complete our preclinical studies or clinical trials; our receipt of regulatory approvals for our product candidates, and the timing of other regulatory filings and approvals; the clinical development, commercialization and market acceptance of our product candidates; our ability to establish and maintain strategic partnerships and other corporate collaborations; the implementation of our business model and strategic plans for our business and product candidates; the scope of protection we are able to establish and maintain for intellectual property rights covering our product candidates and our ability to operate our business without infringing the intellectual property rights of others; competitive companies, technologies and our industry; risks related to the COVID-19 pandemic and the Russian invasion of Ukraine; risks related to not satisfying the continued listing requirements of NYSE American; and statements as to the impact of the political and security situation in Israel on our business. More information on these risks, uncertainties and other factors is included from time to time in the "Risk Factors" section of Can-Fite’s Annual Report on Form 20-F filed with the SEC on March 24, 2022 and other public reports filed with the SEC and in its periodic filings with the TASE. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Can-Fite undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by any applicable securities laws. Contact Details Motti Farbstein Motti@canfite.co.il Company Website https://www.canfite.com

December 27, 2022 08:00 AM Eastern Standard Time

Applied UV Announces $5 Million Secured Revolving Credit Facility

Applied UV, Inc.

Applied UV, Inc. (NASDAQ: AUVI), a pathogen elimination technology company, announced a $5 million secured revolving credit facility effective December 8, 2022. Borrowings under the revolving credit facility will be used for general corporate purposes and to advance Applied UV’s organic and strategic growth initiatives. The facility currently has no outstanding balance. Max Munn, Applied UV, Inc.’s President and Founder, said: "This facility further bolsters our near-term liquidity position and provides us with additional flexibility to execute our growth strategy including the timely delivery of products from an increasing backlog of orders in our hospitality business. Over the past few weeks, we have increased capital availability by $7.5 million with the closing of this new revolver and $2.5 million in an unsecured loan earlier this month. We are taking the steps necessary to ensure we have access to capital to support an acceleration in sales and deliver positive cash flow." Additional details regarding the credit facility are available in a Current Report on the Form 8-K filed with the Securities and Exchange Commission. About Applied UV Applied UV, Inc. ("AUVI") develops and acquires proprietary infection prevention and control technology in the healthcare, commercial & public venue, food processing/storage, cannabis, and education, vertical markets. The company has two wholly owned subsidiaries - SteriLumen, Inc. and Munn Works, LLC. Sterilumen owns and markets a portfolio of products with advanced pathogen elimination technology, branded Airocide® by Sterilumen, Scientific Air™ by Sterilumen, Airoclean™ 420 by Sterilumen, and Lumicide™ by Sterilumen. Leading organizations globally rely on AUVI’s air purification systems to completely eliminate airborne and surface infections, mold, bacteria, allergens and other contaminants. Their customers include Kaiser Permanente, NY Health+Hospitals, Baptist Health South Florida, Boston Red Sox’s Fenway Park, JetBlue Park, France’s Palace of Versailles, Invited Clubs, Whole Foods, Del Monte Foods, U.S. Department of Veterans Affairs and more. NASA used Airocide’s and Airoclean™ 420’s Photocatalytic Oxidation technology to sanitize its International Space Station. Scientifically proven to reduce Healthcare Acquired Infections (HAI), Scientific Air™ offers a proprietary 3-stage technology integrating HEPA filters, ultraviolet germicidal light chamber and active carbon substrate. For information on Applied UV, Inc., and its subsidiaries, please visit the following websites: https://applieduvinc.com/, https://sterilumen.com/ and https://airoclean420.com/. Applied UV is focused on the development and acquisition of technology that addresses infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. (“SteriLumen”) and Munn Works, LLC (“Munn Works”). SteriLumen’s Airocide® air purification devices are research-backed, clinically proven, and developed for NASA with assistance from the University of Wisconsin. Airocide® is listed as an FDA Class II Medical device, utilizes a proprietary photo-catalytic (PCO) bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous airborne pathogens, destructive VOCs, allergens, odors, and biological gasses into harmless water vapor and green carbon dioxide without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine-making facilities, commercial real estate, schools, dental offices, post-harvest, grocery, cannabis facilities, and homes. SteriLumen’s connected platform for Data-Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company’s Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices’ proximity. The Company’s patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen-intensive location. This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investing advice. Contact Details Brett Maas- Hayden IR brett@haydenir.com Company Website https://www.applieduvinc.com/

December 27, 2022 08:00 AM Eastern Standard Time